‹ All Posts
Akshay Patel

5 hours ago · SEBI Registration INH000017231

Piramal Pharma to buy 26% of Yapan Bio going to 100%

Piramal Pharma Limited (NSE: PPLPHARMA) PPLPHARMA has board committee approval to buy the remaining 26% of Yapan Bio Private Limited. That lifts its stake from 74% to 100% and makes the Hyderabad-based CDMO a wholly-owned subsidiary. What happened: Piramal built this stake in steps. It paid ₹101.77 crore for 27.78% in December 2021. In August 2026 it bought a further 40.67% for about ₹76 crore, taking its holding from 33.33% to 74%. The price for the last 26% has not been disclosed yet. Why it matters: Yapan Bio works in biologics and vaccine process development. Full ownership removes the minority interest and the governance overhead that comes with it. Piramal can also pitch Yapan’s capabilities to its North America and Europe customers as one offering. My view: Control was already secured in August, so this step is about alignment, not control. The August deal values Yapan at roughly ₹187 crore for 100% (₹76 crore divided by 40.67%). At that rate, the last 26% would cost about ₹49 crore. That is my estimate, not a disclosed figure. The amount is small, so the strategic fit matters more than the cash outlay. What I am watching: The signing of definitive agreements, the final consideration, and any regulatory approvals. After that, the margin contribution from Yapan’s biologics pipeline and the next quarterly CDMO growth numbers. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations..

#Miscellaneous#TrendingSectors